Clinical Trial Detail

NCT ID NCT03233724
Title The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

non-small cell lung carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST